NCT03910439 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Avelumab 800 mg IV every two weeks in combination with radiation therapy Avelumab: Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle External beam radiotherapy: 5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
- id
- FG000
- title
- 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 4
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 4
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Avelumab 800 mg IV every two weeks in combination with radiation therapy Avelumab: Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle External beam radiotherapy: 5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
- id
- FG000
- title
- 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 4
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 4
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle